

24 Feb 2021 | News

QUOTED. 24 February 2021. Lishan Aklog.

by

PAVmed Inc. subsidiary Lucid Diagnostics will become a separate public company focused on commercializing products for the diagnosis and treatment of esophageal cancer, PAVmed CEO Lishan Aklog said.

“The word is getting out. This is a very consumer-facing activity. People know about heartburn. They know about cancer, and we are starting to get people contacting us saying, ‘I’d like to get this test and where can I get it?’” – Lishan Aklog, CEO, PAVmed

- Find out more: [PAVmed Plans Spin-Off And Marketing Push For Lucid Diagnostics](#)

[Click here](#) for a free trial of *Medtech Insight*